Feasible trial designs for rare neurological populations
Gene therapy trials face a fundamental constraint: small patient populations. When enrollment is limited to dozens — not hundreds — of subjects, endpoint sensitivity becomes the primary determinant of trial feasibility. NeuroQuantix enables powered studies with 3x fewer subjects.
The Small Population Problem
For many neurological gene therapy indications, the global addressable population numbers in the hundreds. Traditional endpoints requiring 50-100 subjects per arm make randomized controlled trials mathematically infeasible. The solution is not to lower the evidentiary bar — it is to use measurement tools with sufficient precision that smaller samples achieve adequate statistical power.
Clinical Applications
Published Evidence
Evidence from peer-reviewed publications supporting digital kinematic endpoints for gene therapy endpoints assessment.
Power Advantage Quantified
With Cohen's d of 1.70 (essential tremor) vs. 0.50 (traditional scales), digital metrics achieve 80% power at n=6 per arm versus n=33 for traditional endpoints.
Computed from Haubenberger et al., 2011 published findings
Cross-Condition Validation
Digital kinematic endpoints have demonstrated high sensitivity across essential tremor, PD, stroke, and DBS populations — supporting applicability across gene therapy target conditions.
Scoping review, 120 studies across 1,407 citations
Regulatory Pathway
FDA DDT qualification and COA framework provide defined pathways for novel endpoint acceptance. Early engagement reduces Phase 3 regulatory risk.
FDA Drug Development Tools qualification program
Statistical Power Advantage
Higher measurement precision translates directly into smaller enrollment requirements. See the full interactive power curve comparison on our product page.
View Power VisualizationReady to discuss gene therapy endpoints endpoints?
Schedule a consultation to explore how precision digital endpoints can strengthen your gene therapy endpoints clinical program.